In this paper, we extend the QMR-DT probabilistic model for the domain of internal medicine to include decisions about treatments. In addition, we describe how we can use the comprehensive decision model to construct a simpler decision model for a specific pa tient. In so doing, we transform the task of problem formulation to that of narrowing of a larger prob lem.
The structuring of problems that serve as the basis for inferential analysis has been considered one of the most ill-characterized phase of machine reason ing [17] Several investigators have speculated that we may never identify principled machinery for prob lem formulation [18, 3] . In this paper, we describe a formal approach to problem formulation in which we reduce a large decision model. In particular, we develop a comprehensive influence diagram for the domain of internal medicine. The model provides recommendations for treating a patient, given obser vations about that patient. To simplify the solution of the comprehensive model, we prune nodes and arcs from the model, based on observations that are specific to a given patient. We conjecture that the patient-specific influence diagram produces treat ment recommendations that are typically identical to those recommendations derived from the compre hensive influence diagram. Previous artificial-intelligence approaches to prob lem formulation-both heuristic and formal involve the direct synthesis of problem-specific mod els rather than the reduction of comprehensive mod els. Researchers have made the assumption ( typ ically implicit) that computer-based reasoning sys tems must be limited to the construction of relatively simple models for action at run time. A heuristic approach to problem formulation can be found in the Present Illness Program (PIP), developed over a decade ago [13] . PIP was designed to assist physi cians with patients presenting with different types of swelling. All possible hypotheses considered by PIP, are stored in the system's long-term memory. Each disease in the knowledge base is associated with a set of observable criteria, called triggers, that are used to make decisions about whether a disease should be considered as active. Information about com peting and complementary diseases is also stored in the long-term memory. A disease is activated, or brought into consideration in PIP's short-term mem ory, when a trigger is observed. Diseases that are competitors or complements also are brought into consideration as semi-active hypotheses. A prob lem, composed of active and semi-active hypothe ses, is addressed with logical and quasi-probabilistic analyses in the working memory. Researchers have pursued heuristic problem formulation methodologies primarily because they reduce the computational burden by selecting a sub set of distinctions for analysis. These heuristic ap proaches, however, are intrinsically limited by their poor characterization. In recent work, spanning ar tificial intelligence and decision science, several in vestigators have developed formal approaches that automate the formulation of decision problems. For example, Wellman has examined the identification of tradeoffs through utility-dominance theorem prov ing (21]. Also, Holtzman (8] and Breese [1] have developed rule-based techniques for constructing in fluence diagrams. In Section 7, we compare our ap proach for problem formulation to these approaches in the context of the internal-medicine domain.
3
Beyond Internist-I:
and QMR-DT QMR Our work is motivated by the QMR-DT, a decision-theoretic decision-support system for inter nal medicine, based on the comprehensive Quick Medical Reference (QMR) knowledge base [7, 5, 16 ]. The QMR reasoning system is the primary descen dant of the Internist-! project at the University of Pittsburgh [15, 12] . The QMR knowledge base was developed, and is being refined, by Miller and other researchers [11] . Over 25 person-years of effort have been directed at the construction of the QMR knowl edge base. QMR (and Internist-!) relies on heuristic nu meric weighting schemes for reasoning under uncer tainty. Several years ago, one of us developed a map ping between these methods and probability theory [6] . That early work, and more recent work within the QMR-DT (for QMR decision-theoretic) research group,1 led to a reformulation of the QMR knowl edge base in the form of a belief network for internal medicine. Figure 1 portrays the general structure of the cur rent QMR-DT belief network. Each disease in the upper layer of the network conditions a subset of manifestations in the lower layer of the network. The actual belief network contains 534 diseases, 4040 manifestations, and a 40740 arcs. Both diseases and manifestations are binary or two-valued distinc tions. Also, diseases are marginally independent, and features are conditionally independent given an instance of diseases (i.e., given an assignment of true or false to each disease). Although not shown in the network, we model the influence of multiple dis eases on a single manifestation using the assump tion of causal independence. In particular, we use Pearl's noisy OR-gate model [14] . In the future, we plan to extend this model to include nonbinary dis eases and manifestations, dependencies among dis eases and manifestations, intermediate pathophys iological states, and manifestations that condition diseases.
The QMR-DT group is currently developing al gorithms for the computation of the marginal poste- rior probability of each disease given instances of one or more of the manifestation nodes. Although this computation is an NP-hard task [4] , preliminary re sults with several algorithms are encouraging. One algorithm, called Quickscore, performs inference ef ficiently when the number of findings observed to be present in a patient is small [5] . Another al gorithm determines bounds on disease probabilities; these bounds shrink as the amount of computation increases [7] . An algorithm based on Monte-Carlo sampling, provides approximate disease probabili ties; the approximations improve as sampling pro gresses [16].
4
From Belief to Action
Determining the probability that single diseases or disease combinations have manifested in a patient is only one component of the internal-medicine prob lem. In addition, an automated reasoner should con sider the possible actions that a physician might take, and the desirability of the possible conse quences of those actions. For example, suppose an expert system determines that the probability that a given patient has syphilis is small-say, 0.01. If the program only considers the likelihoods of dis eases, it will probably fail to suggest to a physician user that he should consider the disease. This failure to suggest the disease to the physician, however, is probably inappropriate, because the side effects of the treatment for syphilis (penicillin) are minimal, and the consequences of the untreated disease are severe.
In the domain of internal medicine, physician ac tions include treatments and other patient interven- tions, and the performance of tests to gather ad ditional information about a patient. In this paper, we extend the QMR-DT model to include treatment actions only. This extension is illustrated by a por tion of an influence diagram for internal medicine shown in Figure 2 . In the diagram, CORNEAL HER PES ZOSTER and CORNEAL HERPES SIMPLEX are two diseases that can cause RED EYE. ACYCLOVIR and PREDNISONE are two treatments for CORNEAL HERPES ZOSTER, whereas ARA-A is a treatment for CORNEAL HERPES SIMPLEX. In general, there can be no treatment, one treatment, or more than one treatment for a given disease. Also, each treatment option may be associated with many (possibly an infinite) number of option alternatives, although in this paper, to keep the discussion simple, we limit the number alternatives for each treatment to two: true and false. The diamond node u represents the overall utility of the patient. The diamond nodes u1, u2, and ua, called subvalue nodes [19, 20] , repre sent components of overall patient utility. The nodes u1 and u3 encode the patient utilities associated with the treatment of CORNEAL HERPES ZOSTER and CORNEAL HERPES SIMPLEX, respectively. The node u2 represents the fact that prednisone therapy can be extremely detrimental to a patient if he has CORNEAL HERPES SIMPLEX. We refer to the entire influence diagram for the QMR domain as the com prehensive decision model.
We measure the utilities underlying the compre hensive model using standard gambles. For exam ple, let us consider the utility associated with the node ua in Figure 2 that corresponds to the situa tion where a patient has CORNEAL HERPES SIMPLEX and is not receiving ARA-A, the only treatment for that disease. To assess this utility, we ask the patient (or an agent of that patient), "Imagine that there is a magic pill that will cure your CORNEAL HERPES SIMPLEX without any side effects with probability p, but will kill you immediately and painlessly with probability 1 -p. What probability p makes you indifferent between taking the pill and remaining in your current situation?" As another example, let us consider the utility that corresponds to the sit uation where the patient does not have CORNEAL HERPES SIMPLEX, and is erroneously receiving ARA A. To assess this utility, we ask the patient ''Imagine that there is a magic pill that will eliminate all side effects of ARA-A with probability q, but will kill you immediately and painlessly with probability 1 -q. What probability q makes you indifferent between taking the pill and remaining in your current situ ation?" Similarly, we can assess the remaining two utilities associated with ua. Most people find these 84 utilities difficult to assess directly, especially when the magic-pill probabilities are small (e.g., q in the previous example). Howard, however, has developed a model that greatly simplifies such assessments [10] .
In constructing the comprehensive decision model for the QMR domain, we assume that the magic-pill probabilities are independent of other diseases that the patient may have and of other treatments that the patient may be receiving. The assumption is a good one, because we can always introduce nodes, as we introduced u2, to represent interactions among diseases and treatments. In making this assump tion of independence, we can select the treatment alternatives that maximize the expected utility of u by choosing those alternatives that maximize the expected utility of each of the u; separately. 2 We thereby reduce the number computations that we require to solve the comprehensive decision model.
5
Problem Formulation as
Large-Model Reduction
The independence assumption we just discussed is a large step toward tractable solutions of the compre hensive decision model. Nonetheless, for most pa tient cases, we shall still require inordinate amounts of time to solve the model. We address this diffi culty by using observations about a given patient to build a patient-specific decision model. This decision model is likely to be smaller than the comprehen sive decision model, and is also likely to give us the same recommendations for action at a lower com putational cost. We view the construction of this model as problem formulation. Before we discuss the construction, let us consider the quantity called P i i , the lowest probability of dis ease di such that treatment a; is warranted by the comprehensive model, given that the patient has at most disease di and receives no other treatments. We compute P i i by setting all diseases except di and all treatments except a; to false, and then solving the comprehensive decision model. The computa tion does not depend on specific observations about a patient. Thus, we have to compute each P i i only once for the comprehensive model. Given the P i i , we can construct a patient-specifi c decision model in two steps. First, given disease manifestations ¢ for a particular patient, we com pute the marginal posterior probability of each dis ease di, denoted p ( di 1¢). If the number of positive 2Such decomposition is possible for any utility model that is additive or multiplicative (9] . The standard gamble model that we describe here is multiplicative. Figure 2 : A portion of the comprehensive decision model for the QMR domain. CORNEAL HERPES ZOSTER and CORNEAL HERPES SIM:PLEX are two diseases that can cause RED EYE. ACYCLOVffi. and PREDNISONE are two treatments for CORNEAL HERPES ZOSTER, whereas ARA-A is a treatment for CORNEAL HERPES SIMPLEX. The overall utility of the patient is represented by the the diamond node labelled u. The diamond nodes u1, u2, and ua, called subvalue nodes, represent components of patient utility that contribute independently to the overall utility of the patient. For example, the node u2 represents the fact that prednisone therapy can be extremely detrimental to a patient if he has Corneal Herpes Simplex. findings in ¢ is small, we can use the Quickscore algorithm to perform this inference. Otherwise, we can use Henrion 's algorithm that provides bounds on these probabilities. In either case, we instantiate ai to false if and only if, for every disease dj that has ai as a possible treatment, the upper bound for the probability of dj falls below p: i for that treatment disease pair. Second, we discard the portions of the comprehensive decision model that are not relevant to the utility of the patient, given those decision vari ables that we have instantiated. A simple algorithm for doing so is as follows: (1) for all subvalue nodes Ui, if all decision-node predecessors of Ui are set to false, then remove Ui from the comprehensive model;
(2) remove all chance and decision nodes that be come disconnected from the node u.
The solution of a patient-specific decision model is likely to be significantly more tractable than that of the comprehensive decision model. One obvious sim plification is that a patient-specifi c decision model will probably contain fewer nodes than the compre hensive decision model. Another, more important, simplification is illustrated by the portion of com prehensive decision model shown in Figure 2 . In particular, suppose our problem-formulation proce dure instantiates PREDNISONE to false for a partic ular patient. In this case, we can solve the ACY CLOVIR and ARA-A portions of the infl uence diagram separately. A similar simplification is illustrated by the portion of the comprehensive decision model in Figure 3 . If the problem-formulation procedure in stantiates THEOPHYLLIN to false, then we can deter mine the decisions of whether or not to administer DIGOXIN and ERYTHROMYCIN independently.
In general, we say that a procedure for pruning a comprehensive decision model is sound if and only if the treatment decisions that are determined by the process of pruning the large model and by solving the reduced model are identical to those decisions de termined by solving the comprehensive model. Our approach is not sound. For example, consider the case where ai is a treatment for diseases dj and dk, but has many side effects. Let us suppose that, for a given patient, the upper bounds for p ( dj 1¢) and p ( dkl¢) fall just below P i j and p: k , respectively. In this situation, our approach instantiates ai to false. Within the comprehensive decision model, however, the treatment ai may be optimal, because the pos itive benefits of ai applied to both diseases may outweigh the negative side effects of the treatment. Nonetheless, we conjecture that such situations will arise rarely. After we construct a substantial subset of the comprehensive decision model for the QMR domain, we shall test this conjecture. 86 We have described our approach for creating a patient-specific decision model in terms of reducing a large comprehensive decision model by instanti ating particular treatment nodes. Alternatively, as illustrated in Figure 4 , we can view this approach as a model-construction process. From this perspective, treatment nodes that are not instantiated to false be come active. In addition, subvalue and chance nodes that are relevant to u, given the instantiated treat ment nodes, become active. The patient-specifi c de cision model is then constructed from these active nodes and from the relationships among these nodes found in the comprehensive decision model.
6
Problem Formulation as a
Metalevel Decision Analysis
We can view our approach as a metalevel decision analysis in which we tradeoff the comprehensiveness of the model with the amount of time required to solve the model. In particular, we have assumed that (1) the cost of including a treatment in a model, given that a full analysis would have proven the treatment should not be undertaken, is small, and (2) the utility of omitting a treatment from a model, given that a full analysis would have indicated the treatment be performed, is large. The first assump tion requires the cost of computation to be small, or that the addition of another distinction (or set of distinctions) does not increase the complexity of the analysis signifi cantly. Additional work is needed to measure such metalevel costs and benefits more ac curately, and to develop procedures for constructing patient-specific models that exploit these measure ments once they are made.
7
Comparison to Other For mal Approaches
We believe that the rule-based and qualitative tradeoff approaches to problem formulation are in adequate for handling the construction of patient specific decision models in the QMR domain. In applying the rule-based approach, an expert would not build a comprehensive decision model. Instead, he would generate rules that correspond to small components of the influence diagram for the QMR domain. For example, one rule might describe the THEOPHYLLINE-DIGOXIN interaction in Figure 3 . The primary drawback of this approach-when ap plied to internal medicine-is that it will be ex tremely difficult for an expert to construct a large set of rules that are consistent. The lack of con sistency is a limitation, because there is no guaran tee that influence diagrams constructed by the rule based approach will be valid unless the rules used to build those diagrams are self consistent [2] . Our ap proach does not suffer from this drawback, because the expert builds an influence diagram for the en tire QMR domain explicitly, and thereby guarantees the self consistency of the knowledge represented in that diagram. Of course, the rule-based approach may be useful in domains where it is impossible or extremely difficult to build an influence diagram for the entire domain. For example, the approach may be useful for stock-market trading, where unforesee able situations arise frequently.
Wellman's approach examines only qualitative in teractions among alternatives, beliefs, and prefer ences. For example, using the approach, we can rep resent the fact that THEOPHYLLINE might relieve the symptoms of ASTHMA, but we cannot represent the degree of belief that these symptoms will be re lieved, nor can we represent the patient's degree of preference for such relief. Given these qualitative interactions, and a set of observations about a pa tient, Wellman's method can identify all decision, chance, and utility variables that might be relevant to the utility of that patient. Unfortunately, almost all variables in the QMR domain might be relevant to a patient's utility at the level of qualitative analy sis. Thus, the approach approach will probably cre ate extremely large patient-specific decision models. We need a more quantitative analysis to produce smaller patient-specifi c decision models whose solu tions are tractable.
Summary
We have described an approach to problem formu lation that uses the results of inference in a belief network to transform a large, comprehensive deci sion model into a smaller, patient-specific decision model. A crucial question is: Will this approach produce patient-specific decision models whose solu tions are both accurate and tractable? We are cur rently implementing our approach within the QMR DT framework to answer this question. Figure 4 : The construction of a patient-specific decision model. First, we apply an inference algorithm to the QMR-DT belief network that produces probabilities or bounds on the probabilities of each disease. Second, we identify treatments that we need to consider. In particular, we make treatment ai active if and only if there is some diseased; for which ai is a possible treatment, such that the upper bound for the probability of d; exceeds Pi ; for that treatment-disease pair. Third, we identify active subvalue and chance nodes as those nodes that are relevant to the decision problem, given the active treatment nodes. The active treatment, subvalue, and chance nodes, and the relationships among these nodes, form the patient-specific decision model, shown at the top of the figure. Nodes that represent disease findings are omitted from the figure. 
